Telehealth existed for decades as a niche: rural specialist consults, tele-stroke, nurse lines, and a handful of employer-paid "doctor on demand" services. In March 2020 the pandemic and emergency waivers turned it, within weeks, into a large share of US outpatient visits, and investors priced the change as permanent. It was partly permanent. Video and audio visits settled at a mid-single-digit share of all claims, concentrated in mental health. Meanwhile direct-to-consumer (DTC) telehealth brands built large cash-pay businesses around prescriptions, and remote monitoring grew into a billing category big enough to attract federal scrutiny. This section covers the modalities, who pays for each, the regulatory rules that decide what can be built, DTC and virtual-first models, the 2020–21 peak and the reset, the evidence, and the landmark companies. The supporting files compute the economics of a remote patient monitoring (RPM) program and tell the story of Teladoc's $18.5 billion Livongo deal.
What the study covers
- 1Overview: what "digital health" actually sells
- 2A short history
- 3Mechanics
- 4The 2020–21 peak and the reset
- 5Key numbers
- 6Landmark companies and cases
- 7The global thread
- 8Pitfalls
- 9How an expert thinks about it
- 10Glossary
Technical exhibits
Worked examples, checklists and case studies included with this study.
Rpm Program Economics Worked Example
A stylized primary-care RPM program under Medicare's code set, with and without the 2026 codes; vendor fee models, engagement, coinsurance and the payer's break-even (computed in Python)
Teladoc Livongo Case Study
The 2020 Teladoc–Livongo merger: thesis, price, integration, the 2022 write-downs and the lessons for "whole-person" virtual-care platforms